Bernstein downgraded Biohaven (BHVN) to Market Perform from Outperform with a price target of $9, down from $34, following Tuesday’s announcement of the complete response letter for troriluzole in SCA. This is a painful downgrade, the firm notes, as Bernstein remains excited about the long-term value of the degrader platform, the original reason for its Outperform rating.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN:
- Biohaven downgraded to Neutral from Buy at BofA
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!
- Midday Fly By: Broader market bought on dip after tech selloff
- Biohaven Ltd.: Strategic Initiatives and Financial Positioning Drive Buy Rating Amid FDA Challenges
- Biohaven downgraded to Market Perform from Outperform at William Blair